KR910004572B1 - 경구용 당뇨병 치료제 제형의 제조방법 - Google Patents

경구용 당뇨병 치료제 제형의 제조방법 Download PDF

Info

Publication number
KR910004572B1
KR910004572B1 KR1019840003189A KR840003189A KR910004572B1 KR 910004572 B1 KR910004572 B1 KR 910004572B1 KR 1019840003189 A KR1019840003189 A KR 1019840003189A KR 840003189 A KR840003189 A KR 840003189A KR 910004572 B1 KR910004572 B1 KR 910004572B1
Authority
KR
South Korea
Prior art keywords
active substance
glycidone
minutes
basic
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019840003189A
Other languages
English (en)
Korean (ko)
Other versions
KR850000241A (ko
Inventor
브리클 롤프
쉐프키 고트프리드
루프레츠트 엑카드
그라이 쉘 안드레아스
Original Assignee
닥터 칼토메 게젤샤프트 미트 베쉬렌크터르 하프퉁
베첼, 조머
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닥터 칼토메 게젤샤프트 미트 베쉬렌크터르 하프퉁, 베첼, 조머 filed Critical 닥터 칼토메 게젤샤프트 미트 베쉬렌크터르 하프퉁
Publication of KR850000241A publication Critical patent/KR850000241A/ko
Application granted granted Critical
Publication of KR910004572B1 publication Critical patent/KR910004572B1/ko
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
KR1019840003189A 1983-06-08 1984-06-07 경구용 당뇨병 치료제 제형의 제조방법 Expired KR910004572B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3320583.3 1983-06-08
DE19833320583 DE3320583A1 (de) 1983-06-08 1983-06-08 Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
KR850000241A KR850000241A (ko) 1985-02-26
KR910004572B1 true KR910004572B1 (ko) 1991-07-06

Family

ID=6200886

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840003189A Expired KR910004572B1 (ko) 1983-06-08 1984-06-07 경구용 당뇨병 치료제 제형의 제조방법

Country Status (24)

Country Link
US (2) US4708868A (cg-RX-API-DMAC10.html)
EP (1) EP0128482B1 (cg-RX-API-DMAC10.html)
JP (1) JPS6075435A (cg-RX-API-DMAC10.html)
KR (1) KR910004572B1 (cg-RX-API-DMAC10.html)
AT (1) ATE49886T1 (cg-RX-API-DMAC10.html)
AU (1) AU562803B2 (cg-RX-API-DMAC10.html)
CA (1) CA1228300A (cg-RX-API-DMAC10.html)
DD (1) DD223360A5 (cg-RX-API-DMAC10.html)
DE (2) DE3320583A1 (cg-RX-API-DMAC10.html)
DK (1) DK162018C (cg-RX-API-DMAC10.html)
ES (1) ES533207A0 (cg-RX-API-DMAC10.html)
FI (1) FI85218C (cg-RX-API-DMAC10.html)
GB (1) GB2142235B (cg-RX-API-DMAC10.html)
GR (1) GR82363B (cg-RX-API-DMAC10.html)
HK (1) HK72287A (cg-RX-API-DMAC10.html)
HU (1) HU192407B (cg-RX-API-DMAC10.html)
IE (1) IE57792B1 (cg-RX-API-DMAC10.html)
IL (1) IL72033A (cg-RX-API-DMAC10.html)
MY (1) MY100764A (cg-RX-API-DMAC10.html)
NO (1) NO168629C (cg-RX-API-DMAC10.html)
NZ (1) NZ208416A (cg-RX-API-DMAC10.html)
PT (1) PT78711B (cg-RX-API-DMAC10.html)
SG (1) SG48087G (cg-RX-API-DMAC10.html)
ZA (1) ZA844295B (cg-RX-API-DMAC10.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5312924A (en) * 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
FR2577437A1 (fr) * 1985-02-21 1986-08-22 Corbiere Jerome Nouveau procede de solubilisation des composes chimiques et les preparations aqueuses ainsi obtenues
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DE3927882A1 (de) * 1989-08-23 1991-02-28 Bauer Kurt Heinz Hochwirksame, schnell resorbierbare zubereitungsformen von glibenclamid, verfahren zu ihrer herstellung und ihre verwendung
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
DE69227240T2 (de) * 1991-01-16 1999-04-08 Fmc Corp., Philadelphia, Pa. Träger für wirkstoffe und damit hergestellte feste darreichungsformen
ATE223391T1 (de) * 1991-06-21 2002-09-15 Boehringer Ingelheim Pharma Verfahren zur herstellung von (s)-3-methyl-1-(2- piperidino-phenyl)-1-butylamin
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US5246711A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US5246710A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US6004958A (en) * 1997-02-05 1999-12-21 Fox Chase Cancer Center Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
US7071298B2 (en) * 1997-02-05 2006-07-04 Fox Chase Cancer Center Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
DE69917618T2 (de) * 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
HK1041451B (en) † 1999-02-08 2006-12-01 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7166301B1 (en) * 1999-05-21 2007-01-23 Kissei Pharmaceutical Co., Ltd. Immediate release medicinal compositions for oral use
US8889182B2 (en) 2001-06-29 2014-11-18 Aptalis Pharma Limited Process of thermodynamical activation of water-insoluble drugs loaded into cross-linked polymers
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
US20050019399A1 (en) * 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
EP1429744A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
US20040151772A1 (en) * 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
EP1562607A1 (en) * 2002-11-15 2005-08-17 Ranbaxy Laboratories, Ltd. Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4989217B2 (ja) * 2003-03-26 2012-08-01 エガレット エイ／エス 薬剤物質の送達制御用マトリックス組成物
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
CN101516347A (zh) * 2006-09-29 2009-08-26 诺沃-诺迪斯克有限公司 包含二甲双胍和瑞格列奈的药物制剂
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
AU2008232937B2 (en) * 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2228066A1 (en) * 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN114805531A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
CN115671203B (zh) * 2022-11-24 2023-10-27 广州中医药大学科技产业园有限公司 一种用于降糖降脂的中药复方提取物及其提取方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668215A (en) * 1967-11-25 1972-06-06 Bayer Ag Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups
NL138933B (nl) * 1969-03-26 1973-05-15 Erba Carlo Spa Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking.
US3708486A (en) * 1969-04-17 1973-01-02 Boehringer Sohn Ingelheim 2-(p-(n'-cycloalkyl-carbamido-n-sulfonyl)-phenethyl)-1,2,3,4-tetrahydro-1,3-dioxo-4,4-dimethyl-isoquinolines and alkali metal salts thereof
NL7314765A (cg-RX-API-DMAC10.html) * 1972-10-31 1974-05-02
DE2657382A1 (de) * 1976-12-17 1978-06-29 Thera Ges Fuer Patente Orales antidiabetikmittel
JPS6026093B2 (ja) * 1978-03-14 1985-06-21 住友製薬株式会社 ゲフアルナート含有固型製剤の製造方法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
ATE22530T1 (de) * 1980-07-29 1986-10-15 Sanofi Sa Durch saeure stabilisierte mischungen von thienopyridinderivaten und verfahren zum verhindern der zersetzung solcher verbindungen.
EP0046961B1 (de) * 1980-08-29 1985-02-13 Byk Gulden Lomberg Chemische Fabrik GmbH Epoxi-cycloalkylalkancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel
DE3225188A1 (de) * 1982-07-06 1984-01-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue phenylessigsaeurederivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3100535A1 (de) * 1981-01-10 1982-08-12 Dr. Karl Thomae Gmbh, 7950 Biberach "neue carbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
GB2118040A (en) * 1982-02-15 1983-10-26 Hoechst Uk Ltd Oral anti-diabetic preparation
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
CA1228300A (en) 1987-10-20
ES8601697A1 (es) 1985-11-16
HUT34349A (en) 1985-03-28
NO168629B (no) 1991-12-09
MY100764A (en) 1991-02-15
EP0128482B1 (de) 1990-01-31
IL72033A0 (en) 1984-10-31
DK162018C (da) 1992-02-10
HK72287A (en) 1987-10-16
GB2142235B (en) 1987-04-08
FI85218C (fi) 1992-03-25
DK162018B (da) 1991-09-09
US4873080A (en) 1989-10-10
NO842291L (no) 1984-12-10
US4708868A (en) 1987-11-24
FI85218B (fi) 1991-12-13
AU2924184A (en) 1984-12-13
DK280884A (da) 1984-12-09
ES533207A0 (es) 1985-11-16
DD223360A5 (de) 1985-06-12
ATE49886T1 (de) 1990-02-15
PT78711A (de) 1984-07-01
NZ208416A (en) 1987-06-30
GR82363B (cg-RX-API-DMAC10.html) 1984-12-13
SG48087G (en) 1987-08-28
IE841422L (en) 1984-12-08
DK280884D0 (da) 1984-06-07
EP0128482A3 (en) 1986-06-25
JPH0548206B2 (cg-RX-API-DMAC10.html) 1993-07-20
AU562803B2 (en) 1987-06-18
PT78711B (de) 1986-10-21
ZA844295B (en) 1986-02-26
IE57792B1 (en) 1993-04-07
EP0128482A2 (de) 1984-12-19
HU192407B (en) 1987-06-29
FI842295A0 (fi) 1984-06-07
IL72033A (en) 1987-08-31
KR850000241A (ko) 1985-02-26
FI842295L (fi) 1984-12-09
NO168629C (no) 1992-03-18
GB2142235A (en) 1985-01-16
JPS6075435A (ja) 1985-04-27
DE3481170D1 (de) 1990-03-08
DE3320583A1 (de) 1984-12-13
GB8414528D0 (en) 1984-07-11

Similar Documents

Publication Publication Date Title
KR910004572B1 (ko) 경구용 당뇨병 치료제 제형의 제조방법
KR910004571B1 (ko) 경구용 당뇨병치료 제제를 제조하는 방법
JP7627302B2 (ja) パルボシクリブの固形剤形
US4556678A (en) Sustained release propranolol tablet
TWI326602B (en) Guaifenesin sustained release formulation and tablets
RU2201754C2 (ru) Фармацевтический состав, способ его получения, способ лечения психотических состояний и гиперактивности
JP2002529407A (ja) Ｌ−ｄｏｐａエチルエステル含有分散性組成物
US20220409701A1 (en) Process for producing a tablet comprising glp-1 peptides
JP2721507B2 (ja) 糖尿病治療剤
CN111329841B (zh) 格列齐特缓释片及其制备方法
US6333361B1 (en) Pharmaceutical composition containing zafirlukast
KR960007753B1 (ko) 피페리디노알칸올 유도체용 제약 조성물
JP5713990B2 (ja) ２型糖尿病治療用の医薬組成物
JP2002534457A (ja) プロフェンと他の活性化合物との組合せを含有する医薬混合物
US20040009971A1 (en) Use of alprazolam in treatment of disorders of the central nervous system
JP2688266B2 (ja) アルドース還元酵素阻害作用を有し且つ吸収性の良好な薬剤組成物
JPH0399018A (ja) グルカゴン様ペプチドホルモン分泌促進剤
JPH047323B2 (cg-RX-API-DMAC10.html)
KR20060087618A (ko) 갑상선 호르몬 약학 제제

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20020621

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030707

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030707

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000